Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2024 07:00 ET | Source: HilleVax, Inc.

HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China

BOSTON and CHENGDU, China, Jan. 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, and...
January 03, 2024 18:28 ET | Source: HilleVax, Inc.

HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
November 09, 2023 16:05 ET | Source: HilleVax, Inc.

HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...
November 01, 2023 16:48 ET | Source: HilleVax, Inc.

HilleVax to Present at Upcoming Investor Conferences

BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
September 26, 2023 16:01 ET | Source: HilleVax, Inc.

HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference

BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
September 25, 2023 07:00 ET | Source: HilleVax, Inc.

HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
September 19, 2023 20:05 ET | Source: HilleVax, Inc.

HilleVax Announces Pricing of Public Offering of Common Stock

BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the...
September 19, 2023 16:09 ET | Source: HilleVax, Inc.

HilleVax Announces Proposed Public Offering of Common Stock

BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
August 14, 2023 07:00 ET | Source: HilleVax, Inc.

HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

BOSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...
May 12, 2023 16:05 ET | Source: HilleVax, Inc.

HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

BOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right